GlassScriptPhysician profile
Jinoos Taef
NPI 1902299555
$13,165.28
in general payments reported to CMS, 2019-2025
33 companies · $2,457 in 2025
The $2,457 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $751 · 2020: $1,513 · 2021: $1,614 · 2022: $2,281 · 2023: $2,279 · 2024: $2,271 · 2025: $2,457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,006.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,728.70 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $2,040.41 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,432.50 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $1,357.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $988.50 | 2019-2025 | |
| Abbvie INC. | $961.72 | 2022-2025 | Ubrelvy, Vraylar, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $811.44 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Biohaven Pharmaceutical Holding Company LTD. | $274.62 | 2022 | |
| Dexcom, INC. | $251.05 | 2021-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $215.09 | 2019-2025 | |
| Abbott Laboratories | $181.58 | 2019-2023 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $170.26 | 2022-2023 | |
| Exact Sciences Corporation | $164.39 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $163.33 | 2023-2025 | Gemtesa, Myfembree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.09 | 2019-2025 | Xifaxan |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $146.06 | 2025 | Auvelity, Symbravo |
| Glaxosmithkline, LLC. | $135.42 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $119.40 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $115.17 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $114.57 | 2021-2025 | Seglentis, Livalo, Zoryve |
| Idorsia Pharmaceuticals US INC | $110.99 | 2022-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $101.19 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $77.98 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $63.72 | 2025 | Voquezna |
| Astellas Pharma US INC | $60.44 | 2019-2020 | |
| Mylan Specialty L.P. | $54.16 | 2020-2021 | |
| Daiichi Sankyo INC. | $32.67 | 2022-2023 | Injectafer |
| Amarin Pharma, INC. | $31.77 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $27.87 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $26.05 | 2025 | Rexulti |
| Lucid Diagnostics INC. | $16.73 | 2023 | |
| Azurity Pharmaceuticals, INC. | $14.84 | 2025 | |
| Dynavax Technologies Corporation | $12.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jinoos Taef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.